Myasthenia Gravis: Symptoms, Diagnosis, and Treatment

Myasthenia gravis (MG) is an autoimmune disease characterized by fluctuating muscle weakness that worsens with use and improves with rest. The hallmark involves muscles that control eye movement, facial expression, swallowing, speech, and limb function. An estimated tens of thousands of Americans live with MG, per the NINDS, with a bimodal age distribution: early-onset disease is more common in women under 40, and late-onset disease is more common in men over 50. The treatment landscape has expanded substantially in the past several years, with several new biologic agents joining traditional therapies.

Read this first. The most dangerous complication of MG is a myasthenic crisis, in which the muscles that power breathing become too weak to work. This is a life-threatening emergency. If you or someone with MG has trouble breathing, cannot clear secretions, is choking, or has rapidly worsening swallowing or speech, call 911 or go to the nearest emergency room immediately. Do not wait.

The Neuromuscular Junction

MG involves antibodies that disrupt communication at the neuromuscular junction, the synapse where motor nerves signal muscles to contract. Most people with generalized MG have antibodies against the acetylcholine receptor (AChR). A smaller share have antibodies against muscle-specific kinase (MuSK), and a smaller group again have antibodies against LRP4. Some patients are seronegative on standard testing despite a clinical picture consistent with MG.

Whatever the specific antibody, the result is impaired neuromuscular transmission: the muscle does not receive enough signal to contract reliably. Repeated activation depletes the available signal, producing the characteristic fatigability, weakness that gets worse the more a muscle is used and better after rest.

Symptoms and Their Pattern

Ocular symptoms, drooping eyelids (ptosis) and double vision (diplopia), are the presenting feature in about half of patients and eventually develop in the large majority. Symptoms typically worsen later in the day or after sustained eye use such as reading or driving.

Bulbar symptoms, meaning slurred or nasal speech, difficulty swallowing, choking on liquids, and weakness when chewing, affect a significant subset and can dominate in MuSK-positive disease. Limb weakness, typically proximal (shoulders and hips), affects most patients with generalized MG. Neck-flexor weakness producing head drop, and breathing-muscle weakness in severe cases, complete the picture. The MedlinePlus overview underscores that weakness “gets worse with activity and better with rest,” a pattern that helps distinguish MG from many other causes of weakness.

The fatigable pattern is characteristic. Holding the arms outstretched for a minute or two reproduces weakness, and sustained upgaze brings out ptosis. Placing ice on a drooping eyelid for a couple of minutes often improves it transiently; this simple bedside ice-pack maneuver can support the diagnosis and is described by centers such as the Cleveland Clinic.

Diagnosis

Diagnosis combines clinical features, antibody testing, and electrophysiology. AChR antibody testing is the first-line lab; if it is negative in suspected generalized MG, MuSK and LRP4 antibody testing follows.

Repetitive nerve stimulation shows a decremental response in a majority of generalized MG patients. Single-fiber EMG, the most sensitive test, shows increased “jitter” in almost all MG patients but requires specialized expertise. Edrophonium (Tensilon) testing has largely fallen out of favor because of safety concerns and is rarely used today.

CT or MRI of the chest is standard at diagnosis to evaluate for a thymoma (a thymus-gland tumor), which occurs in a notable minority of MG patients and changes management. Thyroid function should be checked given the autoimmune association. Autoimmune diseases including thyroid disease, lupus, and rheumatoid arthritis cluster more often in people with MG, so clinicians often screen accordingly.

Symptomatic Treatment

Pyridostigmine (Mestinon) is an acetylcholinesterase inhibitor that increases available acetylcholine at the neuromuscular junction. It is typically the first treatment, providing symptomatic relief without addressing the underlying autoimmunity. Dosing is individualized and set by the prescribing neurologist; there is no one-size-fits-all schedule, and higher amounts can produce cholinergic side effects such as cramping, diarrhea, salivation, and muscle twitching. Never adjust the dose on your own, and report new or worsening symptoms to your clinician.

Pyridostigmine is generally less effective in MuSK-positive MG and may even worsen symptoms in some MuSK patients. Most patients ultimately need immunomodulatory therapy in addition to, or instead of, pyridostigmine.

Immunomodulatory Therapy

Corticosteroids (such as prednisone) are commonly used to suppress the autoimmune process and often produce marked improvement. Initial dosing requires care, because high-dose steroids can cause a transient worsening (sometimes called the “steroid dip”) in the first weeks, occasionally precipitating crisis. For this reason, many neurologists start steroids cautiously or in the hospital for moderate-to-severe disease. Steroid dosing and tapering are prescriber-directed and should never be self-managed.

Steroid-sparing immunosuppressants, including azathioprine, mycophenolate mofetil, methotrexate, cyclosporine, and tacrolimus, allow long-term tapering of steroids. Their benefit typically takes many months to appear, so they are started with realistic expectations about timing.

For acute exacerbations and crisis, plasma exchange (PLEX) and intravenous immunoglobulin (IVIG) work within days to weeks and are used as bridges to slower-acting therapies.

Rituximab, particularly useful in MuSK-positive MG, is increasingly used. Newer targeted biologics have reshaped options for refractory disease. They include the complement inhibitors eculizumab (Soliris), ravulizumab (Ultomiris), and zilucoplan (Zilbrysq), and the neonatal Fc receptor (FcRn) inhibitors efgartigimod (Vyvgart) and rozanolixizumab (Rystiggo), which lower circulating IgG, including the pathogenic antibodies. More recently, nipocalimab (Imaavy), another FcRn blocker, was approved for generalized MG; because this area is changing quickly, confirm the current list of approved agents and their eligibility with your neurologist and verify current FDA labeling. Annual list prices for these newer agents are high, often in the six-figure range, though insurance and manufacturer assistance can substantially reduce out-of-pocket cost. Our healthcare costs overview covers strategies for managing high-cost specialty medications.

Thymectomy

Surgical removal of the thymus has been a treatment option for decades, and its role was clarified by the MGTX trial (published 2016, with extension data reported through 2019), which showed improved outcomes and reduced steroid use in AChR-positive patients roughly aged 18 to 65 with generalized MG, even without a thymoma. Patients with a thymoma should have it surgically removed when feasible.

Thymectomy benefits emerge over months to years. Robotic and minimally invasive thoracoscopic approaches have reduced the recovery burden compared with traditional open sternotomy. Whether thymectomy is appropriate depends on antibody status, age, and other factors, and is decided with your care team.

Myasthenic Crisis: A Medical Emergency

Myasthenic crisis is severe weakness affecting the respiratory muscles, requiring intubation or non-invasive ventilation. It is a life-threatening emergency. A meaningful minority of MG patients experience a crisis in their lifetime, most often within the first couple of years after diagnosis. Triggers include infection (especially respiratory infections), surgery, certain medications, pregnancy, physical or emotional stress, heat, and sometimes the start or escalation of corticosteroids.

When to seek emergency care: Call 911 or go to the nearest emergency room if you experience severe shortness of breath, an inability to clear secretions, choking that does not resolve, severe weakness that prevents standing or holding the head up, or rapid worsening of swallowing or speech. Myasthenic crisis requires ICU-level care, often with non-invasive or invasive ventilation, plus treatments such as IVIG or plasma exchange. A cholinergic crisis from too much pyridostigmine can mimic a myasthenic crisis but adds autonomic features such as excessive salivation, sweating, GI symptoms, and small pupils; both are emergencies that warrant urgent evaluation.

Because certain drugs can worsen MG or trigger crisis, the medications to be used with caution or avoided, which can include some antibiotics (such as aminoglycosides, fluoroquinolones, and certain macrolides), intravenous magnesium, some beta-blockers, neuromuscular blocking agents, certain anesthetics, and occasionally other drugs, are managed with your neurologist rather than by self-editing your regimen. The Myasthenia Gravis Foundation of America maintains a regularly updated cautionary-drugs list for patients and clinicians. Always tell any new clinician, dentist, or anesthesiologist that you have MG before a prescription or procedure.

Living With Myasthenia Gravis

Daily routines can be built around fatigue patterns. Many people schedule important activities when their strength tends to be best, often in the morning, and build in rest breaks proactively rather than reactively. Symptom diaries help identify personal patterns and triggers.

Heat worsens MG for many patients, so hot weather, hot showers, and saunas can trigger fatigue; air conditioning, cool clothing, and shifting outdoor activity to cooler times can help. Vaccination is generally recommended (with live vaccines avoided during strong immunosuppression, per your clinician). Pregnancy planning benefits from coordination between neurology and maternal-fetal medicine; many women have stable or improved MG during pregnancy with careful monitoring. Our medical conditions overview covers chronic disease management more broadly.

When to See a Doctor

A new, unexplained drooping eyelid, double vision, slurred speech, swallowing difficulty, or fatigable weakness warrants a neurology evaluation. Established MG patients should have a low threshold for evaluation of new or worsening weakness or breathing symptoms, and before any planned surgery or new medication.

Many clinicians recommend MG-specific medical-alert identification given the drug interactions and emergency considerations. Patient organizations such as the Myasthenia Gravis Foundation of America provide education and can connect patients to specialty MG centers.

Frequently Asked Questions

Is myasthenia gravis fatal?

With modern treatment, mortality has fallen dramatically compared with a century ago. Myasthenic crisis remains the main acute risk and is treatable in well-equipped centers. Most patients today live near-normal lifespans with appropriate care.

Can myasthenia gravis go into remission?

Yes. With effective treatment, many patients achieve sustained minimal symptoms or pharmacologic remission, and some achieve remission off all therapy, though that is less common. Remission is more likely after thymectomy in AChR-positive patients.

Is myasthenia gravis hereditary?

Acquired autoimmune MG is not directly inherited, though a general genetic susceptibility to autoimmunity can run in families. Congenital myasthenic syndromes, which are distinct inherited conditions that present in childhood, are separate from autoimmune MG.

What medications should I avoid with myasthenia gravis?

Several drugs can worsen MG, and the specific list is best managed with your neurologist rather than self-applied, because the right choice always depends on your situation. Categories that often require caution include certain antibiotics, intravenous magnesium, some anesthetics, neuromuscular blocking agents, and some cardiac medications. Always inform clinicians about MG before any new prescription or procedure, and consult the MGFA cautionary-medications list with your care team.